| Class: | Serotonin–dopamine releasing agent |
| Cas Number: | 882302-56-9 |
| Pubchem: | 82281626 |
| Chemspiderid: | 26702454 |
| Unii: | TAS3L629HH |
| Synonyms: | 3-MeOMC; meta-Methoxymethcathinone; m-MeOMC; 3-Methoxy-N-methylcathinone; 3-Methoxy-N-methyl-β-ketoamphetamine; 3-Methoxy-α,N-dimethyl-β-ketophenethylamine |
| Iupac Name: | 1-(3-methoxyphenyl)-2-(methylamino)propan-1-one |
| C: | 11 |
| H: | 15 |
| N: | 1 |
| O: | 2 |
| Smiles: | CC(C(=O)C1=CC(=CC=C1)OC)NC |
| Stdinchi: | 1S/C11H15NO2/c1-8(12-2)11(13)9-5-4-6-10(7-9)14-3/h4-8,12H,1-3H3 |
| Stdinchikey: | VAVRRUJYUFACKA-UHFFFAOYSA-N |
3-Methoxymethcathinone (3-MeOMC), also known as meta-methoxymethcathinone (m-MeOMC), is a designer drug of the substituted cathinone family described as a stimulant.[1] [2] [3]
Similarly to other cathinones, it acts as a monoamine releasing agent, including of serotonin, dopamine, and norepinephrine.[4] [5] However, in contrast to cathinones and amphetamines, 3-MeOMC appears to show selectivity for induction of serotonin and dopamine release over release of norepinephrine, and hence may act as a partially selective serotonin–dopamine releasing agent (SDRA). Its values are 129nM for dopamine release and 306nM for serotonin release in vitro, whereas it only induced 68% release of norepinephrine at a concentration of 10μM. For comparison, other related cathinones, including cathinone, methcathinone, 3-methylmethcathinone (3-MMC; metaphedrone), 4-methylmethcathinone (4-MMC; mephedrone), and 4-methoxymethcathinone (4-MeOMC; methedrone), induced 94 to 101% release of norepinephrine at 10μM. However, in another publication, the of 3-MMC for induction of norepinephrine release was 111nM, and hence it did not appear to show selectivity for induction of serotonin and dopamine release relative to norepinephrine, instead acting as a serotonin–norepinephrine–dopamine releasing agent (SNDRA).
3-MeOMC first appeared as an illicit drug after 2014.